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The discovery of tumor necrosis factor (TNF) superfamily dates back to the middle of the 
nineteenth century when O‘Malley found a tumor-necrotizing factor in the serum that could 
mediate tumor regression effects [1]. Carswell‘s group renamed this factor as tumor necrosis 
factor and reported that macrophages were the source of this factor [2]. In 1968, Granger and 
colleagues described another factor called lymphotoxin (LT) produced by lymphocytes, which 
could also kill tumor cells [3]. Until 1984, Aggarwal‘s group determined and compared the 
amino acid sequence of TNF and LT, indicating that the two proteins were homologous [4]. 
Therefore, they were renamed to TNF-α and TNF-β, respectively. These two factors laid the 
foundation for the identification of the TNF superfamily.  
At present, in total 19 TNF superfamily ligands and 29 receptors have been identified (shown 
in Table. 1). The TNF superfamily ligands are type II trimeric transmembrane proteins with a 
C-terminal TNF homology domain (THD). THD is a sequence of around 150 amino acids, 
which contains a conserved framework of aromatic and hydrophobic residues to fold and form 
trimeric proteins [5]. The individual monomers are β-sandwich structures containing β strands 
and loops that form a ―jelly-roll‖ structure: the inner sheets are responsible for trimerization 
and the outer sheets are for receptor binding [5,6]. The TNF superfamily receptors are type I 
or type III membrane or soluble proteins containing cysteine-rich domains (CRD) for ligand 
binding [7].  
Among the large family of TNF ligands and receptors, there are 19 ligands and 29 different 
receptors, indicating the diversity of ligand-receptor interactions. As shown in Table. 1, TNF 
ligands can bind to one specific or multiple receptors, and different ligands can bind to the 
same receptor. The TNF receptors can be divided into 3 groups according to their cytoplasmic 
sequences and their cellular signal pathways [8]. The first group receptors, including Fas, 
TNFR1, DR3, DR4, DR5, and DR6, contain a death domain (DD) in the cytoplasmic tail. 
Activation of these DD-containing receptors can lead to the recruitment of adaptor proteins 
such as TNFR associated death domain (TRADD) or Fas-associated death domain (FADD), 
which on their turn can activate the caspase cascade and finally induce apoptosis [9]. The 
second group, including TNFR2, CD40, CD30, CD27, LTβR, OX40, 4-1BB, BAFFR, BCMA, 
TACI, RANK, NGFR, HVEM, GITR, TROY, EDAR, XEDAR, RELT, and Fn14, contains 
TNFR associated factor (TRAF)-interacting motifs (TIM). Activation of these TIM-
containing receptors can lead to the activation of downstream signaling pathways, including 




nuclear factor-κB (NF-κB), mitogen-associated protein kinases (MAPK) such as p38, c-JNK, 
and the extracellular signal-regulated kinases (ERK) as well as phosphoinositide 3-kinase 
(PI3K) and Akt [8,10], which finally induce cell survival and inflammation. The third group 
of TNF receptors includes Decoy receptor 1 (DcR1), DcR2, DcR3, and osteoprotegerin 
(OPG), which do not contain functional intracellular signaling domains or motifs. They act as 
decoy receptors to compete and block the binding between the ligand and other functional 
receptors [8,11,12].  
Almost all of the TNF superfamily ligands are expressed by immune cells, while the receptors 
are expressed by a wide variety of cells [13]. The binding between the TNF superfamily 
ligands and receptor will cause biological effects such as tumor regression, immune system 
regulation and hematopoiesis. However, dysregulation of the binding between the ligand and 
receptor also leads to various diseases [13]. In this thesis, we mainly focus on two TNF 
superfamily members, RANKL and TRAIL.  
Table 1: Ligands and receptors of TNF superfamily [7] 
Ligands  Receptors 
Symbol Common name (alias)  Common name 
TNFSF1 TNF-α  TNFR1/TNFR2 
TNFSF2 TNF-β (LT-α)  TNFR1/TNFR2/HVEM/ LTβR 
TNFSF3 LT-β  LTβR 
TNFSF4 OX40L (CD252)  OX40 
TNFSF5 CD40L (CD154)  CD40 
TNFSF6 FasL (CD95L/Apo1L)  Fas/DcR3 
TNFSF7 CD27L (CD70)  CD27 
TNFSF8 CD30L (CD153)  CD30 
TNFSF9 4-1BBL  4-1BB 
TNFSF10 TRAIL (Apo2L)  DR4/DR5/DcR1/DcR2/OPG 
TNFSF11 RANKL (OPGL/ODF/TRANCE)  RANK/OPG 
TNFSF12 TWEAK (Apo3L)  Fn14 
TNFSF13 APRIL (TALL-2/TRDL-1)  TACI/BCMA 
TNFSF13B BAFF (BLYS/THANK)  BAFF-R/TACI/BCMA 
TNFSF14 LIGHT (HVEML/LT-γ)  LTβR/DcR3/HVEM 
TNFSF15 VEGI (TL1A)  DcR3/DR3 
TNFSF18 GITRL  GITR 
 EDA-A1  EDAR 
 EDA-A2  XEDAR 
 N.D.  DR6 
 N.D.  RELT 
 N.D.  TROY 







In 1981, Rodan and Martin formulated a detailed hypothesis that osteoblasts influence the 
formation of osteoclasts [14]. In the late 1990s, OPG was discovered and patented as an 
important regulator of bone density [15]. Subsequent research was undertaken to identify the 
ligand of OPG, and contemporaneously an alternative strategy was used to identify TNFR 
superfamily homologous. As a result, the ligand of receptor activator of nuclear factor κB 
(RANKL), also known as OPGL, ODF and TRANCE, and its receptor RANK were 
discovered by different independent groups [16–18].  
The RANKL/RANK/OPG system was first found to play an important role in bone 
remodeling system [19]. In normal conditions, bone homeostasis is maintained by a balance 
between old bone resorption by osteoclasts and new bone formation by osteoblasts [20]. 
RANKL is expressed on osteoblasts and RANK is expressed on osteoclast precursor cells 
[21]. The interaction between RANKL and RANK can induce the differentiation of 
osteoclasts from osteoclast precursors, and promote osteoclasts activation and survival [20]. 
The essential signaling pathway after RANKL stimulation includes the adaptor protein 
TNFR-associated factors (TRAFs) recruitment, NF-κB activation and translocation, and 
osteoclastogenic genes transcription [22]. OPG, which is also produced by osteoblasts, is a 
soluble decoy receptor and competes with RANK for RANKL binding [23]. Imbalances in the 
RANK/RANKL/OPG pathway can dysregulate the bone remodeling to either bone formation 
or resorption, therefore leading to diseases such as osteoporosis or osteopetrosis. 
Apart from the role in bone remodeling, RANKL/RANK signaling also plays important roles 
in other tissues, since they are produced by a variety of cell types and tissues [22]. Recent 
studies indicate a number of other physiological and pathophysiological processes involving 
RANKL/RANK pathways like glandular development and lactation, cancer cell proliferation 
and metastasis and adaptive immunity [24]. More interestingly, this system may also play a 
role in fibrosis, which is characterized by excessive accumulation of extracellular matrix 
(ECM) [25]. In bone tissue, RANKL can bind to RANK on osteoclasts and induce bone ECM 
degradation. However, whether and how this signaling pathway regulates fibrotic tissue ECM 
degradation is unclear up to now. 
Due to the important roles of the RANK-RANKL pathway in bone and other tissues, targeting 
RANKL or RANK with either agonistic or antagonistic compounds is a promising strategy 
for therapeutic intervention. Initially, OPG-Fc/variants or RANKL-targeted peptides were 




developed as RANKL scavengers to prevent bone loss and inflammation [21,26,27]. 
Furthermore, denosumab, an FDA-approved RANKL-specific antibody, was developed and 
used in the treatment of osteoporosis and bone metastases [28]. However, through titrating 
away RANKL but not the receptor, they all carry the risk of immune reactions. Therefore, 
strategies with less immune response are still needed. One other approach was to focus on 
novel structure-based RANKL variants, which might be of interest to target the receptor 
directly and trigger the autoimmune system with less impact compared to antibody. 
 
TRAIL and its receptors 
TNF-related apoptosis inducing ligand (TRAIL), also known as Apo2 ligand (Apo2L), was 
discovered in 1995 [29,30]. It is an important ligand protein of TNF superfamily that 
selectively induces apoptosis in a variety of tumor cells [31]. TRAIL interacts with five 
cognate receptors, namely death receptor 4 (DR4/TRAIL-R1), death receptor 5 (DR5/TRAIL-
R2), decoy receptor 1 (DcR1/TRAIL-R3), decoy receptor 2 (DcR2/TRAIL-R4), and the 
soluble receptor osteoprotegerin (OPG) [32]. Both DR4 and DR5 contain the death domain 
(DD) in the intracellular part. Therefore, upon binding to DR4 and DR5, TRAIL can activate 
the extrinsic pathway through the recruitment of the Fas-associated death domain and the 
activation of caspase-8 [9,33]. The other receptors act as decoys receptors since DcR1 lacks a 
cytosolic region and DcR2 only contains a truncated, non-functional death domain [34]. OPG 
is a soluble protein showing weaker affinity to TRAIL compared to other membrane-bound 
receptors. However, it can still block the induction of apoptosis through sequestering the 
available TRAIL [35]. 
TRAIL can initiate the extrinsic apoptosis pathway through binding to DR4 or DR5, which 
results in the recruitment of caspase-8 and FADD to form the death-inducing signaling 
complex (DISC) [9]. This can further activate the downstream effector caspase-3, caspase-6, 
and caspase-7 and result in apoptosis [36]. In some cases, DISC activation is not sufficient to 
trigger the caspase cascade and the activation of the intrinsic pathway gets involved. Caspase-
8 activation cleaves Bid to truncated Bid (tBid), which further interacts with Bax and Bak on 
the mitochondrial membrane to promote the release of apoptotic factors like cytochrome c. 
These factors will form the apoptosome through binding to apoptotic peptidase activating 
factor 1 (Apaf-1) and the initiator caspase-9, which in turn activates caspase-3, caspase-6, and 




Although TRAIL has been recognized as a representative anti-cancer agent, TRAIL resistance 
in tumor cells has been considered as a problem for a long time. This resistance may occur at 
different levels in the signaling pathways, including decoy receptors competition and 
dysregulation, DISC inhibition, reduced caspase function, imbalance of anti-and pro- proteins 
expression [35,38]. Therefore, the understanding of the mechanisms of TRAIL resistance and 
ways to improve TRAIL sensitivity of tumor cells is important for the development of 
therapeutic approaches with TRAIL. 
Recombinant human TRAIL (rhTRAIL, aa 114-281) has been mostly used and developed as a 
clinical anti-cancer drug [39,40]. Clinical phase I studies showed this rhTRAIL was safe in 
patients with advanced cancer. However, there was no clinical benefit of rhTRAIL due to its 
fast kinetics and short half-life. On the other hand, rhTRAIL binds to all five TRAIL receptors, 
including three decoy receptors, which interfere with TRAIL-induced apoptosis. To overcome 
TRAIL resistance caused by decoy receptors competition, DR-specific TRAIL variants or 
antibodies are becoming promising therapeutic approaches in cancer treatment. 
 
Scope of the thesis 
The work described in this thesis is aimed to probe the ligand-receptor interface of TNF 
superfamily members RANKL and TRAIL, and the design and characterization of novel 
recombinant RANKL and TRAIL variants for their use as potential therapeutics. 
Bone, as a dynamic tissue, is maintained by continuous renewal. An imbalance in bone 
resorption and formation can lead to a range of disorders, such as osteoporosis or 
osteopetrosis. The RANK/RANKL pathway plays an important role in bone remodeling. In 
Chapter 2, we review the prospective of interfering with the RANK/RANKL pathway as a 
therapeutic target for bone diseases and discuss the role of the soluble receptor OPG as a 
therapeutic in bone diseases. Then we focus on the possibility to develop antagonistic and 
agonistic variants of RANKL based on computational protein design. Finally, we discuss the 
development of antagonistic RANKL variants by changing the stoichiometry of the RANKL 
molecule. 
In Chapter 3, we investigate the effect of mutations at position I248 in the DE-loop of 
RANKL on the interaction of RANKL with RANK and subsequent osteoclastogenesis 
activation. Two single mutants, RANKL I248Y and I248K, were found to maintain binding 




and have the ability to reduce wild type RANKL-induced osteoclastogenesis. The generation 
of RANK-antagonists based on RANKL structure is a promising strategy for the exploration 
of new therapeutic approaches against osteoporosis. 
RANKL/RANK/OPG signaling system was found to play an important role in the regulation 
of ECM formation and degradation in bone tissue. However, whether and how this signaling 
pathway plays a role in fibrotic tissue ECM degradation is unclear up to now. Interestingly, 
increased decoy receptor OPG levels are found in fibrotic tissues. In Chapter 4, we 
investigate the role of RANKL/RANK/OPG pathway in fibrosis. We hypothesize that 
RANKL can stimulate RANK on macrophages and induce the process of ECM degradation. 
This process may be inhibited by highly expressed OPG in fibrotic conditions. In this case, 
RANKL mutants that can bind to RANK without binding to OPG might become promising 
therapeutic candidates. We built a structure-based library containing 44 RANKL mutants and 
found that RANKL_Q236D can activate RAW cells to initiate the process of ECM 
degradation and is able to escape from the obstruction by exogenous OPG.  
In Chapter 5, to achieve a delivery system for targeting RANKL_Q236D to the fibrotic 
tissues, without influencing the bone remodeling, we constructed replication-deficient 
adenoviruses Ad-RANKL WT and Ad-RANKL Q236D. The functionality of virally produced 
RANKL_WT and RANKL_Q236D was confirmed, and it turned out that virally produced 
RANKL_Q236D can activate RAW 264.7 cells and make them escape from the inhibition by 
exogenous OPG. The generation of Ad-RANKL Q236D is a powerful tool that might lead to 
new therapies against fibrosis. 
Since OPG also acts as the decoy receptor of TRAIL, we are also interested in the ligand-
receptor interface of TRAIL and its receptors, and TRAIL resistance caused by its decoy 
receptors. In Chapter 6, we compare the sensitivity of TRAIL in senescent and proliferating 
cancer cells. We found that therapy-induced senescence resulted in an increased expression of 
the pro-apoptotic TRAIL receptor death receptor 5 (DR5), as well as an increase in TRAIL 
decoy receptors DcR1, DcR2, and soluble decoy receptor OPG. A DR5 selective TRAIL 
variant (DHER), which is unable of binding to OPG, DcR1 or DR4, is more effective in 
inducing apoptosis of senescent breast cancer cells compared to wild-type TRAIL. 
High expression of OPG is also found in breast tumor cells, which inhibits TRAIL-induced 
apoptosis. Chapter 7 reports on a structure-based design strategy to obtain TRAIL variants 




triple mutant TRAIL_D269H/Y209M/K179P showed lowered binding to OPG compared to 
TRAIL_DHER, and these variants can induce apoptosis in breast cancer cells MDA-MB-231 
and MDA-MB-436 in the presence of OPG.   
In Chapter 8, we summarize the work presented in this thesis and describe some suggestions 
for future perspectives. 
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